Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ATHE
ATHE logo

ATHE Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Alterity Therapeutics Ltd (ATHE) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
3.560
1 Day change
-2.23%
52 Week Range
7.000
Analysis Updated At
2026/03/27
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Alterity Therapeutics Ltd (ATHE) is not a strong buy at this time for a beginner investor with a long-term strategy. The stock is currently in a bearish technical trend, lacks positive news or catalysts, and has no significant trading signals from Intellectia Proprietary Trading Signals. With no recent financial data or valuation metrics available, and no significant insider or hedge fund activity, it is advisable to hold off on investing in this stock until more favorable conditions emerge.

Technical Analysis

The technical indicators for ATHE are bearish. The MACD is negatively expanding, RSI is neutral at 30.135, and moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below key pivot levels, with support at 3.215 and resistance at 3.406.

Positive Catalysts

  • NULL identified. No recent news or events to act as positive catalysts.

Neutral/Negative Catalysts

  • is also down by 1.79%. Technical indicators and moving averages suggest a bearish trend.

Financial Performance

No financial data available for the latest quarter.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target data available.

Wall Street analysts forecast ATHE stock price to rise
Analyst Rating
0
Wall Street analysts forecast ATHE stock price to rise
Buy
Hold
Sell
0
Current: 3.636
sliders
Low
0
Averages
0
High
0
0
Current: 3.636
sliders
Low
0
Averages
0
High
0
Canaccord
Speculative Buy
initiated
$A1.6c
AI Analysis
2025-12-17
Reason
Canaccord
Price Target
$A1.6c
AI Analysis
2025-12-17
initiated
Speculative Buy
Reason
Canaccord initiated coverage of Alterity Therapeutics with a Speculative Buy rating and $A1.6c price target. Alterity is developing ATH434 for the treatment of synucleinopathy-driven neurodegenerative diseases such as multiple system atrophy and Parkinson's disease, the analyst tells investors in a research note. The firm says ATH434 addresses an unmet need.

People Also Watch